Communications Biology (Nov 2022)
Alteration in tyrosine phosphorylation of cardiac proteome and EGFR pathway contribute to hypertrophic cardiomyopathy
- Mingguo Xu,
- Kevin C. Bermea,
- Marzieh Ayati,
- Han Byeol Kim,
- Xiaomei Yang,
- Andres Medina,
- Zongming Fu,
- Amir Heravi,
- Xinyu Zhang,
- Chan Hyun Na,
- Allen D. Everett,
- Kathleen Gabrielson,
- D. Brian Foster,
- Nazareno Paolocci,
- Anne M. Murphy,
- Genaro A. Ramirez-Correa
Affiliations
- Mingguo Xu
- Department of Pediatrics/Division of Cardiology, Johns Hopkins University School of Medicine
- Kevin C. Bermea
- Department of Pediatrics/Division of Cardiology, Johns Hopkins University School of Medicine
- Marzieh Ayati
- Deparment of Computer Science/College of Engineering and Computer Science, University of Texas Rio Grande Valley School of Medicine
- Han Byeol Kim
- Department of Neurology/Institute for Cell Engineering, Johns Hopkins University School of Medicine
- Xiaomei Yang
- Department of Anesthesiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Andres Medina
- Department of Molecular Science/UT Health Rio Grande Valley
- Zongming Fu
- Department of Pediatrics/Division of Hematology, Johns Hopkins University School of Medicine
- Amir Heravi
- Department of Pediatrics/Division of Cardiology, Johns Hopkins University School of Medicine
- Xinyu Zhang
- Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University
- Chan Hyun Na
- Department of Neurology/Institute for Cell Engineering, Johns Hopkins University School of Medicine
- Allen D. Everett
- Department of Pediatrics/Division of Cardiology, Johns Hopkins University School of Medicine
- Kathleen Gabrielson
- Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine
- D. Brian Foster
- Department of Medicine/Division of Cardiology, Johns Hopkins University School of Medicine
- Nazareno Paolocci
- Department of Medicine/Division of Cardiology, Johns Hopkins University School of Medicine
- Anne M. Murphy
- Department of Pediatrics/Division of Cardiology, Johns Hopkins University School of Medicine
- Genaro A. Ramirez-Correa
- Department of Pediatrics/Division of Cardiology, Johns Hopkins University School of Medicine
- DOI
- https://doi.org/10.1038/s42003-022-04021-4
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 17
Abstract
Quantitative global phosphotyrosine proteomics of two mouse models of hypertrophic cardiomyopathy reveals that tyrosine kinase inhibitors may be a future therapeutic approach for treating hypertrophic cardiomyopathy.
